<DOC>
	<DOCNO>NCT01438554</DOCNO>
	<brief_summary>The purpose study determine safety toxicity combination pazopanib GSK1120212 patient solid tumor identify maximum tolerate dose ( MTD ) combination phase II study .</brief_summary>
	<brief_title>Phase 1 Study Pazopanib With GSK1120212 Advanced Solid Tumors , Enriched With Patients With Differentiated Thyroid Cancer , Soft-tissue Sarcoma , Cholangiocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<criteria>Dose escalation cohort solid tumor close enrollment . Expansion cohort : Softtissue sarcoma , cholangiocarcinoma , differentiate thyroid cancer ( DTC ) cohort close enrollment . Patients DTC cohort must disease able biopsied . Must measurable disease . Tumor progression 6month period prior study drug initiation . DTC patient : must radioiodine nonavid lesion , OR radioiodine avid lesion respond treatment radioactive iodine . ECOG performance status less equal 1 . Life expectancy &gt; 3 month . Blood pressure &lt; 140 mmHg &lt; 90 mmHg . LVEF &gt; = 50 % Must able swallow pill . Chemotherapy , radiotherapy , investigational therapy , major surgery within 4 week . Sarcoma cholangiocarcinoma ONLY : Prior VEGFtargeted TKI therapy . Pregnant currently breastfeed . Unresolved toxicity great grade 1 . Evidence active hepatitis HIV . Significant cardiovascular disease . Taking medication know strong inducer inhibitor CYP3A enzymes . Clinically significant gastrointestinal abnormality may increase risk gastrointestinal bleeding . History gastrointestinal condition cause malabsorption obstruction . Cerebrovascular accident include transient ischemic attack ( TIA ) , pulmonary embolism untreated deep vein thrombosis ( DVT ) within past 6 month . Known endobronchial lesion and/or lesion infiltrate major pulmonary vessel increase risk pulmonary hemorrhage . Hemoptysis within 6 month start treatment . History retinal vein occlusion ( RVO ) central serous retinopathy ( CSR ) , predispose factor RVO CSR assess ophthalmic exam . Known brain mets stable least 8 week prior treatment , patient glucocorticoid brain mets .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>